Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) Revenue (2021 - 2025)

Historic Revenue for Neuphoria Therapeutics (NEUP) over the last 3 years, with Q2 2025 value amounting to -$13267.0.

  • Neuphoria Therapeutics' Revenue changed N/A to -$13267.0 in Q2 2025 from the same period last year, while for Dec 2025 it was $15.0 million, marking a year-over-year increase of 216141.45%. This contributed to the annual value of $15.6 million for FY2025, which is N/A changed from last year.
  • Per Neuphoria Therapeutics' latest filing, its Revenue stood at -$13267.0 for Q2 2025.
  • Neuphoria Therapeutics' 5-year Revenue high stood at $15.0 million for Q1 2025, and its period low was -$295982.6 during Q4 2021.
  • Over the past 3 years, Neuphoria Therapeutics' median Revenue value was $324724.0 (recorded in 2024), while the average stood at $3.8 million.